CA3248348A1 - SOLVATE AND CRYSTALLINE SALINE FORMS OF MURIZATOCLAX (AMG 397) - Google Patents
SOLVATE AND CRYSTALLINE SALINE FORMS OF MURIZATOCLAX (AMG 397)Info
- Publication number
- CA3248348A1 CA3248348A1 CA3248348A CA3248348A CA3248348A1 CA 3248348 A1 CA3248348 A1 CA 3248348A1 CA 3248348 A CA3248348 A CA 3248348A CA 3248348 A CA3248348 A CA 3248348A CA 3248348 A1 CA3248348 A1 CA 3248348A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- xrpd pattern
- radiation
- crystalline
- amg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306781P | 2022-02-04 | 2022-02-04 | |
| US63/306,781 | 2022-02-04 | ||
| PCT/US2023/012252 WO2023150250A1 (en) | 2022-02-04 | 2023-02-03 | Crystalline salt and solvate forms of murizatoclax (amg 397) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248348A1 true CA3248348A1 (en) | 2023-08-10 |
Family
ID=86054183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248348A Pending CA3248348A1 (en) | 2022-02-04 | 2023-02-03 | SOLVATE AND CRYSTALLINE SALINE FORMS OF MURIZATOCLAX (AMG 397) |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250122224A1 (enExample) |
| EP (1) | EP4472985A1 (enExample) |
| JP (1) | JP2025505142A (enExample) |
| AU (1) | AU2023215171A1 (enExample) |
| CA (1) | CA3248348A1 (enExample) |
| MX (1) | MX2024009650A (enExample) |
| WO (1) | WO2023150250A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519271A1 (en) | 2022-05-04 | 2025-03-12 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
-
2023
- 2023-02-03 WO PCT/US2023/012252 patent/WO2023150250A1/en not_active Ceased
- 2023-02-03 US US18/730,353 patent/US20250122224A1/en active Pending
- 2023-02-03 JP JP2024545809A patent/JP2025505142A/ja active Pending
- 2023-02-03 MX MX2024009650A patent/MX2024009650A/es unknown
- 2023-02-03 AU AU2023215171A patent/AU2023215171A1/en active Pending
- 2023-02-03 CA CA3248348A patent/CA3248348A1/en active Pending
- 2023-02-03 EP EP23718377.7A patent/EP4472985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023215171A1 (en) | 2024-07-04 |
| JP2025505142A (ja) | 2025-02-21 |
| US20250122224A1 (en) | 2025-04-17 |
| EP4472985A1 (en) | 2024-12-11 |
| MX2024009650A (es) | 2024-08-14 |
| WO2023150250A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3205653B1 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
| AU2014286047A1 (en) | Crystalline forms of ponatinib hydrochloride | |
| US20250122224A1 (en) | Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397) | |
| CA3046027A1 (en) | Crystalline salts and polymorphs of a p2x3 antagonist | |
| US20250115622A1 (en) | Crystalline Forms Of An MCL-1 Inhibitor | |
| US12351588B2 (en) | Salt forms and solvates of Mcl-1 antagonists | |
| US20240140966A1 (en) | Amorphous and crystalline forms of mcl-1 antagonists | |
| US20250002453A1 (en) | Pharmaceutically acceptable salt of eliglustat and crystal form thereof | |
| CZ201769A3 (cs) | Pevné formy venetoclaxu | |
| KR20250132529A (ko) | 리나프라잔 글루레이트의 하이드로브로마이드 염의 다형체 | |
| TW202102510A (zh) | 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物 | |
| JP2026503096A (ja) | リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）のマレイン酸塩の多形 | |
| KR20210017070A (ko) | 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도 | |
| EP3517529B1 (en) | Salt of quinazoline derivative, preparation method therefor and application thereof | |
| KR20260059498A (ko) | 바이사이클릭 헤테로사이클릴 화합물의 신규 염 및 이의 결정형 | |
| AU2023307494A1 (en) | Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-fluorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof | |
| TW202302597A (zh) | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 | |
| CA3219303A1 (en) | Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| JPWO2020045475A1 (ja) | ピラゾロ［３，４−ｄ］ピリミジンの結晶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240704 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241212 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241212 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241212 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260122 |